Phase 2 Trial Assesses c-Abl Inhibitor for Early Parkinson’s
In a landmark clinical advancement poised to reshape the therapeutic landscape of neurodegenerative disorders, researchers have unveiled compelling data on vodobatinib, a selective c-Abl tyrosine...
















